[Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy]

Ann Med Interne (Paris). 2001 Feb;152(1):11-4.
[Article in French]

Abstract

From March to July 1996, 61 patients with CD4<50/mm(3)began a therapy with protease inhibitors. Increase and maintenance of CD4>100/mm(3) was observed in 39/61 patients with a protective effect for occurrence of AIDS or death. This immunological response was correlated with the duration of the virological response. However, 38% of patients with long-term immunological response never had a undetectable viral load.

Publication types

  • English Abstract

MeSH terms

  • CD4 Lymphocyte Count*
  • Disease Progression
  • Follow-Up Studies
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • HIV Infections / mortality
  • HIV Infections / virology
  • HIV Protease Inhibitors / immunology*
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Indinavir / immunology*
  • Indinavir / therapeutic use*
  • Ritonavir / immunology*
  • Ritonavir / therapeutic use*
  • Saquinavir / immunology*
  • Saquinavir / therapeutic use*
  • Time Factors
  • Treatment Outcome
  • Viral Load

Substances

  • HIV Protease Inhibitors
  • Indinavir
  • Saquinavir
  • Ritonavir